LON:STX

Shield Therapeutics (STX) Share Price, News & Analysis

Shield Therapeutics logo
GBX 3.05 +0.05 (+1.67%)
As of 11:32 AM Eastern

About Shield Therapeutics Stock (LON:STX)

Advanced

Key Stats

Today's Range
2.92
▼
3.20
50-Day Range
3
▼
5.96
52-Week Range
2.92
▼
12.50
Volume
1.50 million shs
Average Volume
2.47 million shs
Market Capitalization
£32.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc. (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. Feraccru® is commercialized in the UK and European Union by Norgine B.V. (Norgine), which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer®/ Feraccru® in China, Hong Kong, Macau and Taiwan; with Korea Pharma Co., Ltd. for the Republic of Korea (Korea Pharma); and with KYE Pharmaceuticals Inc. for Canada. Accrufer®/Feraccru® has patent coverage until the mid-2030s. Accrufer®/Feraccru® are registered trademarks of Shield Therapeutics.

Receive STX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shield Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

STX Stock News Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More Headlines

STX Stock Analysis - Frequently Asked Questions

Shield Therapeutics' stock was trading at GBX 10 at the beginning of 2026. Since then, STX shares have decreased by 69.5% and is now trading at GBX 3.05.

Shield Therapeutics plc (LON:STX) released its quarterly earnings data on Thursday, April, 24th. The company reported GBX (3) earnings per share (EPS) for the quarter. Shield Therapeutics had a negative net margin of 17.76% and a positive trailing twelve-month return on equity of 64.57%.

Shares of STX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Shield Therapeutics investors own include Seeing Machines (SEE), Allogene Therapeutics (ALLO), Atlantic Lithium (ALL), Beeks Financial Cloud Group (BKS), Currys (CURY), Fresnillo (FRES) and ITM Power (ITM).

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
LON:STX
CIK
N/A
Fax
N/A
Employees
40,000
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
GBX (1)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-£36.28 million
Net Margins
-17.76%
Pretax Margin
N/A
Return on Equity
64.57%
Return on Assets
-47.85%

Debt

Debt-to-Equity Ratio
-146.28
Current Ratio
0.75
Quick Ratio
2.16

Sales & Book Value

Annual Sales
£58.63 million
Price / Sales
0.56
Cash Flow
GBX 0.48 per share
Price / Cash Flow
6.36
Book Value
GBX 0.05 per share
Price / Book
55.73

Miscellaneous

Outstanding Shares
1,074,194,000
Free Float
N/A
Market Cap
£32.76 million
Optionable
Not Optionable
Beta
1.77
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (LON:STX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners